Xilio Therapeutics Growth Metrics (2024-2025) | XLO

Growth Metrics Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025
Growth Ratios
Assets Growth (1y) 25.55%48.89%79.08%
Assets (QoQ) 8.79%-16.93%-4.80%45.92%29.02%-0.09%
Capital Expenditures Growth (1y) 1,290.48%
Capital Expenditures (QoQ) -33.33%4,766.67%-55.14%
Cash & Equivalents Growth (1y) 162.21%62.18%69.39%
Cash & Equivalents (QoQ) 120.57%-18.27%-9.74%61.15%36.42%-14.63%
Cash from Investing Activities (QoQ) 33.33%-266.67%-1,722.73%
Cash from Operations Growth (1y) 375.93%-172.56%-27.96%
Cash from Operations (QoQ) 289.99%-168.52%-3.55%304.69%-149.96%-20.85%
EBITDA Margin Growth (1y) 39,480.0053,411.00
EBITDA Margin (QoQ) -2874.00-13992.0030,672.0025,674.0011,057.00
EBIT Growth (1y) 2.30%86.93%
EBIT Margin Growth (1y) 44,613.0064,220.00
EBIT Margin (QoQ) -2848.00-13823.0031,781.0029,502.0016,759.00
EBIT (QoQ) -0.39%7.68%-1.63%-3.72%86.57%
EBT Growth (1y) 2.30%86.93%
EBT Margin Growth (1y) 44,613.0064,220.00
EBT Margin (QoQ) -2848.00-13823.0031,781.0029,502.0016,759.00
EBT (QoQ) -0.39%7.68%-1.63%-3.72%86.57%
Enterprise Value Growth (1y) -162.21%-62.18%-69.39%
Enterprise Value (QoQ) -120.57%18.27%9.74%-61.15%-36.42%14.63%
EPS (Basic) Growth (1y) 33.33%50.00%
EPS (Basic) (QoQ) 8.33%-15.77%29.33%11.11%31.25%
EPS (Weighted Average and Diluted) Growth (1y) 33.33%50.00%
EPS (Weighted Average and Diluted) (QoQ) 8.33%-15.77%29.33%11.11%31.25%
FCF Margin Growth (1y) -102724.0051,279.00
FCF Margin (QoQ) -145109.00-21697.00180,056.00-115975.008,894.00
Free Cash Flow Growth (1y) 372.60%-173.21%-27.88%
Free Cash Flow (QoQ) 289.61%-168.57%-3.52%302.54%-150.92%-19.76%
Net Cash Flow Growth (1y) 453.88%-18.78%-29.93%
Net Cash Flow (QoQ) 518.89%-134.21%56.44%666.82%-3.86%-154.73%
Net Income Growth (1y) 2.30%86.93%
Net Income (QoQ) -0.39%7.68%-1.63%-3.72%86.57%
Net Income towards Common Stockholders Growth (1y) 2.30%86.93%
Net Income towards Common Stockholders (QoQ) -0.39%7.68%-1.63%-3.72%86.57%
Net Margin Growth (1y) 44,613.0064,220.00
Net Margin (QoQ) -2848.00-13823.0031,781.0029,502.0016,759.00
Operating Income Growth (1y) 2.30%86.93%
Operating Income (QoQ) -0.39%7.68%-1.63%-3.72%86.57%
Operating Margin Growth (1y) 44,613.0064,220.00
Operating Margin (QoQ) -2848.00-13823.0031,781.0029,502.0016,759.00
Profit After Tax Growth (1y) -3.17%86.24%
Profit After Tax (QoQ) -0.68%6.61%-1.58%-8.02%86.57%
Property, Plant & Equipment (Net) Growth (1y) -22.61%-21.78%-24.07%
Property, Plant & Equipment (Net) (QoQ) -7.31%-5.68%-7.70%-4.09%-6.32%-8.44%
Return on Assets (QoQ) -6.0017.0015.00
Return on Capital Employed (QoQ) 57.0030.00
Return on Equity (QoQ) -179.00-235.009,170.00
Return on Sales Growth (1y) 446.00642.00
Return on Sales (QoQ) -28.00-138.00318.00295.00168.00
Revenue Growth (1y) 242.98%742.51%
Revenue (QoQ) -3.99%-23.82%69.95%175.90%135.85%
Share-based Compensation Growth (1y) -16.26%-10.59%-28.65%
Share-based Compensation (QoQ) -17.57%4.17%-3.68%1.25%-11.99%-16.88%
Shareholder's Equity Growth (1y) -58.47%-78.85%-138.60%
Shareholder's Equity (QoQ) 29.70%-37.23%-16.10%-39.20%-33.93%-214.51%